Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BENETHERA (BEIJING) BIOTECHNOLOGY CO., LTD. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, NGUYEN, QUANG. The prosecution is restricted to 1 distinct art unit, indicating a narrow technical focus for the company's active biotechnology filings. This concentration within a single art unit can lead to a more specialized examination of the pharmaceutical claims.
The busiest examiner, NGUYEN, QUANG, manages 1 pending office action. Given that there is only 1 distinct examiner and 1 pending action, the company's current prosecution efforts are entirely concentrated. This provides a singular point of interaction for the company's pharmaceutical intellectual property at the patent office. The busiest examiner pending figure of 1 confirms that the company's current prosecution strategy is entirely centered on the feedback from this specific individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 1 | 37.8% | +52.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998855 | T CELL, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998855 | T CELL, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | NGUYEN, QUANG | 1631 | §103 | Non-Final OA | — | Pending | Nov 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBENETHERA (BEIJING) BIOTECHNOLOGY CO., LTD. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Quang Nguyen has the most, with 1 of BENETHERA (BEIJING) BIOTECHNOLOGY CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.